The insertion of the 3-bromo-4-hydroxybenzylidene portions at the 3,5 positions of the 1-benzylpiperidin-4-one yielded 2 (Figure 1), inactive against PRMT1, SET7, and p300 HAT, and exhibiting selective inhibition of CARM1 [17] and EZH2 (unpublished results), a KMT highly involved in cancer diseases. Here, EZH2 is linked to cancer.